Enzon acquired the worldwide rights excluding Nordic region to develop, manufacture and commercialize the Phase I drug (rhMBL) from Natimmune. The drug is estimated to generate billions of dollars in sales each year. After having been forced to halt the development of several key pipeline drugs and terminate several deals, Enzon has made an attempt to reinstate its oncology pipeline through this deal.